|
|
|
Scientific Literature, corticosteroid
-
Abad C, Gomariz RP, Waschek JA 2006 Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP.
Curr. Top. Med. Chem. 6: 151-163.
-
Abdelli MN, Ben Abdallah H, Houissa F, Bouali MR, Khediri MF 2007 Azathioprine for prevention of postoperative recurrence in Crohn's disease.
Tunis. Med. 85: 569-572.
-
Abdo AA, Beck P 2003 Diagnosis and management of microscopic colitis.
Can. Fam. Physician 49: 1473-1478.
-
Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T, Garrity J, Goeken JA, Allen NB 2002 Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s.
J. Rheumatol. 29: 309-316.
-
Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, Horiike N, Onji M 2003 Drug-induced hepatitis with autoimmune features during minocycline therapy.
Intern. Med. 42: 48-52.
*
-
Abe M, Onji M, Kawai-Ninomiya K, Michitaka K, Matsuura B, Hiasa Y, Horiike N 2007 Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis.
Clin. Gastroenterol. Hepatol. 5: 255-258.
-
Abely M 2007 Treatment of airway inflammation in cystic fibrosis.
Arch. Pediatr. 14: 1350-1355.
-
Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD 2005 Antibiotic use and the risk of flare of inflammatory bowel disease.
Clin. Gastroenterol. Hepatol. 3: 459-465.
*
-
Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR 2003 Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.
Gastroenterology 125: 320-327.
*
-
Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD 2007 Risk for active tuberculosis in inflammatory bowel disease patients.
Clin. Gastroenterol. Hepatol. 5: 1070-1075.
-
Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, Bouhnik Y, Coffin B, Allez M, Lamarque D, Chaussade S 2007 A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
Clin. Gastroenterol. Hepatol. 5: 1184-1189.
-
Abitbol V, Mary JY, Roux C, Soule JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S; Groupe D'etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) 2002 Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride.
Aliment. Pharmacol. Ther. 16: 919-927.
*
-
Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B 1995 Metabolic bone assessment in patients with inflammatory bowel disease.
Gastroenterology 108: 417-422.
*
-
Aboian E, Winter DC, Metcalf DR, Wolff BG 2006 Perineal hernia after proctectomy: prevalence, risks, and management.
Dis. Colon Rectum 49: 1564-1568.
*
-
Abourazzak FE, Guggenbuhl P, Perdriger A, Meadeb J, Gando-Cocley N, Chevrant-Breton J, Hajjaj-Hassouni N, Chales G 2008 Cutaneous lupus induced by etanercept in rheumatoid arthritis.
Rev. Med. Interne. 29: 744-747.
-
Abraham NS, El-Serag HB, Johnson ML, Hartman C, Richardson P, Ray WA, Smalley W 2005 National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs.
Gastroenterology 129: 1171-1178.
*
-
Abramovits W, Stevenson LC 2005 Atopic profiles, familial histories, and coexisting conditions associated with hand eczema.
Skinmed. 4: 204-210.
-
Abreu MT 2002 The pathogenesis of inflammatory bowel disease: translational implications for clinicians.
Curr. Gastroenterol. Rep. 4: 481-489.
-
Aceves SS, Bastian JF, Newbury RO, Dohil R 2007 Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children.
Am. J. Gastroenterol. 102: 2271-2279.
*
-
Ackermann D 2007 Hypercalcemia in sarcoidosis - case report, prevalence, pathophysiology and therapeutic options.
Ther. Umsch. 64: 281-286.
-
Ackermann D, Mordasini D, Cheval L, Imbert-Teboul M, Vogt B, Doucet A 2007 Sodium retention and ascites formation in a cholestatic mice model: role of aldosterone and mineralocorticoid receptor?
Hepatology 46: 173-179.
*
-
Actis GC, Fadda M, Pellicano R, David E, Rizzetto M, Sapino A 2008 The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis.
Biomed. Pharmacother. Jul 9 [Epub ahead of print].
-
Actis GC, Pellicano R, Bugianesi E, Lagget M, Rizzetto M 2008 Use of corticosteroids, immunomodulators, and Infliximab at a third-level day-hospital service of gastro-hepatology.
Minerva Gastroenterol. Dietol. 54: 239-242.
-
Adachi JD, Rostom A 1999 Metabolic bone disease in adults with inflammatory bowel disease.
Inflamm. Bowel Dis. 5: 200-211.
-
Adcock IM, Ito K, Barnes PJ 2005 Histone deacetylation: an important mechanism in inflammatory lung diseases.
COPD 2: 445-455.
-
Adler AI, Gunn E, Haworth CS, Bilton D 2007 Characteristics of adults with and without cystic fibrosis-related diabetes.
Diabet. Med. 24: 1143-1148.
*
-
Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D 2008 Genetic determinants and epidemiology of cystic fibrosis-related diabetes - results from a British cohort of children and adults.
Diabetes Care 31: 1789-1794.
-
Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP 1991 Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo.
Dig. Dis. Sci. 36: 449-453.
-
Aggarwal A, Catlett JP 2002 Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
South. Med. J. 95: 1209-1212.
-
Agoumi S, Himdi B, Abidi K, Zeggwagh A, Abouqal R 2006 Acute pancreatitis revealing a systemic lupus erythematous.
Rev. Med. Interne. 27: 799-802.
-
Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM 2005 Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease.
Clin. Gastroenterol. Hepatol. 3: 1215-1220.
-
Aguirre AL, Center SA, Randolph JF, Yeager AE, Keegan AM, Harvey HJ, Erb HN 2007 Gallbladder disease in Shetland sheepdogs: 38 cases (1995-2005).
J. Am. Vet. Med. Assoc. 231: 79-88.
-
Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, Schechter GP 2004 Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Am. J. Hematol. 77: 171-176.
*
-
Ahmed I, Harshad SR 2006 Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?
J. Am. Acad. Dermatol. 54: 55-60.
-
Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R 2006 Risk of postoperative infection in patients with inflammatory bowel disease.
Korean J. Gastroenterol. 48: 306-312.
-
Ahn KS, Aggarwal BB 2005 Transcription factor NF-kappaB: a sensor for smoke and stress signals.
Ann. N. Y. Acad. Sci. 1056: 218-233.
*
-
Ajisaka H, Fujita H, Kaji M, Maeda K, Yabushita K, Konishi K, Uchiyama A, Miwa A 2002 Lymphoplasmacytic sclerosing pancreatocholangitis successfully treated by pancreatoduodenectomy.
J. Hepatobiliary Pancreat. Surg. 9: 522-526.
-
Ajit C, Suvannasankha A, Zaeri N, Munoz SJ 2003 Terbinafine-associated hepatotoxicity.
Am. J. Med. Sci. 325: 292-295.
-
Akamatsu S, Tsukazaki H, Inoue K, Nishio Y 2005 A case of lupus cystitis diagnosed from urinary symptoms as the sole initial complaint.
Hinyokika. Kiyo. 51: 685-687.
-
Akerman L, Mimouni D, Trattner A, David M 2006 Pemphigus vulgaris - an alternative for steroid treatment?
Harefuah. 145: 493-494, 551.
-
Akkoc N, van der Linden S, Khan MA 2006 Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
Best Pract. Res. Clin. Rheumatol. 20: 539-557.
-
Akobeng A, Thomas A 2007 Enteral nutrition for maintenance of remission in Crohn's disease.
Cochrane Database Syst. Rev. 3: CD005984.
*
-
Akobeng A, Zachos M 2004 Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
Cochrane Database Syst. Rev. 1: CD003574.
*
-
Akobeng AK 2008 Crohn's disease: current treatment options.
Arch. Dis. Child. 93: 787-792.
-
Akobeng AK 2008 Review article: the evidence base for interventions used to maintain remission in Crohn's disease.
Aliment. Pharmacol. Ther. 27: 11-18.
*
-
Akobeng AK, Gardener E 2004 Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
Cochrane Database Syst. Rev. 1: CD003715.
*
-
Akritidis N, Papadopoulos A, Pappas G 2006 Long-term follow-up of patients with adult-onset Still's disease.
Scand. J. Rheumatol. 35: 395-397.
*
-
Al Shammeri O, Duerksen DR 2008 Celiac crisis in an adult on immunosuppressive therapy.
Can. J. Gastroenterol. 22: 574-576.
-
Al-Aghbar MN, Alexander GJ, Neuberger J, Nouri-Aria KT, Eddleston AL, Williams R 1986 The effect of prednisolone in vitro on immunoglobulin production in primary biliary cirrhosis.
Clin. Exp. Immunol. 63: 663-670.
*
-
Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG 1981 Allopurinol hepatotoxicity. Report of two cases and review of the literature.
Ann. Intern. Med. 95: 588-590.
-
Al-Khalidi JA, Czaja AJ 2001 Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis.
Mayo Clin. Proc. 76: 1237-1252.
*
-
Al-Mutawa SA, Hegab SM 2004 Behcet's disease.
Clin. Exp. Med. 4: 103-131.
*
-
Al-Osaimi AM, Berg CL 2002 Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature.
Am. J. Gastroenterol. 97: S85. *
-
Al-toma A, Verbeek WH, Mulder CJ 2007 The management of complicated celiac disease.
Dig. Dis. 25: 230-236.
-
Al-Toma A, Verbeek WH, Mulder CJ 2007 Update on the management of refractory coeliac disease.
J. Gastrointestin. Liver Dis. 16: 57-63.
*
-
Alam I, Levenson SD, Ferrell LD, Bass NM 1997 Diffuse intrahepatic biliary strictures in sarcoidosis resembling sclerosing cholangitis. Case report and review of the literature.
Dig. Dis. Sci. 42: 1295-1301.
*
-
Alfadhli A, McDonald J, Feagan B 2005 Methotrexate for induction of remission in refractory Crohn's disease.
Cochrane Database Syst. Rev. 1: CD003459.
*
-
Alfadhli AA, McDonald JW, Feagan BG 2003 Methotrexate for induction of remission in refractory Crohn's disease.
Cochrane Database Syst. Rev. 1: CD003459.
*
-
Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H 2007 Prevalence and risk factors of osteoporosis in female SLE patients - extended report.
Rheumatology (Oxford) 46: 1185-1190.
*
-
Alvarez F 2004 Round table: controversies in the treatment of autoimmune liver diseases in children. Cyclosporine indication in “autoimmune hepatitis (AIH)”.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 95-96. *
-
Amano K, Amano K 1998 Filter leukapheresis for patients with ulcerative colitis: clinical results and the possible mechanism.
Ther. Apher. 2: 97-100.
-
Amarapurkar DN, Patel ND, Amarapurkar AD 2003 Hepatic sarcoidosis.
Indian J. Gastroenterol. 22: 98-100.
-
Ament ME, Berquist W, Vargas J 1988 Advances in ulcerative colitis.
Pediatrician 15: 45-57.
-
Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A 2004 SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.
Rheumatology (Oxford) 43: 658-661.
*
-
Ammar D, Denguezli M, Ghariani N, Sriha B, Belajouza C, Nouira R. 2007 Sweet's syndrome complicating isotretinoin therapy in acne.
Ann. Dermatol. Venereol. 134: 151-154.
-
Anavekar NS, Williams R, Chong AH 2007 Sweet's syndrome in an Australian hospital: a retrospective analysis.
Australas. J. Dermatol. 48: 161-164.
*
-
Andre MF, Aumaitre O, Piette JC, Grateau G, Cardoso MC, Ouchchane L, Kemeny JL, Dastugue B, Delpech M, Creveaux I 2008 Analysis of the NOD2/CARD15 gene in patients affected with the aseptic abscesses syndrome with or without inflammatory bowel disease.
Dig. Dis. Sci. 53: 490-499.
*
-
Andre MF, Piette JC, Kemeny JL, Ninet J, Jego P, Delevaux I, Wechsler B, Weiller PJ, Frances C, Bletry O, Wismans PJ, Rousset H, Colombel JF, Aumaitre O; and the French Study Group on Aseptic Abscesses 2007 Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature.
Medicine (Baltimore) 86: 145-161.
-
Andreassen H, Rungby J, Dahlerup JF, Mosekilde L 1997 Inflammatory bowel disease and osteoporosis.
Scand. J. Gastroenterol. 32: 1247-1255.
-
Andus T, Gross V, Caesar I, Schulz HJ, Lochs H, Strohm WD, Gierend M, Weber A, Ewe K, Scholmerich J; German/Austrian Budesonide Study Group 2003 Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
Dig. Dis. Sci. 48: 373-378.
*
-
Angelova-Fischer I, Tsankov N 2005 Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.
Acta Dermatovenerol. Alp. Panonica Adriat. 14: 115-119.
*
-
Angulo P 2002 Use of ursodeoxycholic acid in patients with liver disease.
Curr. Gastroenterol. Rep. 4: 37-44.
-
Angulo P, Bharucha AE, Jorgensen RA, DeSotel CK, Sandborn WJ, LaRusso NF, Lindor KD 1999 Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study.
Dig. Dis. Sci. 44: 602-607.
*
-
Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD 2000 Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Hepatology 31: 318-323.
*
-
Angulo P, Lindor KD 1998 Management of primary biliary cirrhosis and autoimmune cholangitis.
Clin. Liver Dis. 2: 333-351, ix.
-
Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M 2005 Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study.
Am. J. Gastroenterol. 100: 1370-1375.
*
-
Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Muller S, Senninger N, Russell J, Jauch J, Bergmann J, Granger DN, Krieglstein CF 2006 Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis.
Am. J. Physiol. Gastrointest. Liver Physiol. 290: G1131-G1137.
*
-
Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, Boumpas DT 2007 Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease.
Clin. Exp. Rheumatol. 25: 23-28.
-
Antoniu SA 2007 Treatment options for refractory Wegener's granulomatosis: a role for rituximab?
Curr. Opin. Investig. Drugs 8: 927-932.
-
Antoniu SA 2007 Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al.: infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. (2006) 174(7):795-802.
Expert Opin. Investig. Drugs 16: 753-756.
-
Antoniu SA 2006 Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?
Expert Opin. Investig. Drugs 15: 181-184.
-
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, de Bruin PA, Mieremet-Ooms MA, van der Zon JM, van Tol EA, Lamers CB 1989 In vitro cellular cytotoxicity in Crohn's disease and ulcerative colitis: relation with disease activity and treatment, and the effect of recombinant gamma-interferon.
J. Clin. Lab. Immunol. 29: 119-124.
-
Arai F, Takahashi T, Furukawa K, Matsushima K, Asakura H 1998 Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease.
Dig. Dis. Sci. 43: 2071-2079.
*
-
Arakawa Y, Hashida N, Ohguro N, Yamazaki N, Onda M, Matsumoto S, Ohishi M, Yamabe K, Tano Y, Kurokawa N 2008 Eye-concentrated distribution of dexamethasone carried by sugar-chain modified liposome in experimental autoimmune uveoretinitis mice.
Biomed. Res. 28: 331-334.
-
Arash A, Shirin L 2008 The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid.
J. Oral Pathol. Med. 37: 341-344.
-
Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R 2007 Early versus late surgery for ileo-caecal Crohn's disease.
Aliment. Pharmacol. Ther. 26: 1303-1312.
*
-
Ardizzone S 2003 Ulcerative colitis.
Orphanet encyclopedia [http://www.orpha.net/data/patho/GB/uk-UC.pdf]. *
-
Arechalde A, Saurat JH 2000 Management of psoriasis: the position of retinoid drugs.
BioDrugs 13: 327-333.
-
Arend LJ, Springate JE 2004 Interstitial nephritis from mesalazine: case report and literature review.
Pediatr. Nephrol. 19: 550-553.
*
-
Arguelles Arias F, Arguelles Martin F, Caunedo Alvarez A, Rodriguez-Tellez M, Herrerias Gutierrez JM 2003 Utility of capsule endoscopy in pediatric gastroenterology.
An. Pediatr. (Barc.) 59: 586-589.
-
Arimura Y, Goto A, Yamashita K, Endo T, Ikeda H, Tanaka K, Tsutsumi H, Shinomura Y, Imai K 2006 Intractable colitis associated with chronic granulomatous disease.
J. Med. Microbiol. 55: 1587-1590.
*
-
Arish N, Eldor R, Fellig Y, Bogot N, Laxer U, Izhar U, Rokach A 2006 Lymphocytic interstitial pneumonia associated with common variable immunodeficiency resolved with intravenous immunoglobulins.
Thorax 61: 1096-1097.
*
-
Arnold C, von Sanden S, Theilacker C, Blum HE 2008 Ulcerous colitis and infection with cytomegalovirus, herpes simplex virus and Clostridium difficile.
Z. Gastroenterol. 46: 780-783.
-
Aronoff JS, Korelitz BI, Sohn N, Ky A, Rajapakse R, Weinstein MA, Cohen FS 2000 Anorectal Crohn's disease: surgical and medical management.
BioDrugs 13: 95-105.
-
Arundel C, Lewis JH 2007 Drug-induced liver disease in 2006.
Curr. Opin. Gastroenterol. 23: 244-254.
-
Arzoo K, Sadeghi S, Liebman HA 2002 Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
Ann. Rheum. Dis. 61: 922-924.
*
-
Asashima N, Fujimoto M, Jinnin M, Ihn H, Kikuchi K, Takamizawa M, Tamaki K 2004 A female case of hyper-IgM immunodeficiency syndrome with uncommon skin manifestations.
Nihon Rinsho Meneki Gakkai Kaishi 27: 350-355.
-
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC 2005 Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
BMJ 330: 516.
*
-
Asherson RA 2006 The catastrophic antiphospholipid (Asherson's) syndrome.
Autoimmun. Rev. 6: 64-67.
-
Ashraf VV, Taly AB, Veerendrakumar M, Rao S 2006 Myasthenia gravis in children: a longitudinal study.
Acta Neurol. Scand. 114: 119-123.
*
-
Assimakopoulos SF, Michalopoulou S, Melachrinou M, Giannakoulas N, Papakonstantinou C, Lekkou A, Gogos C 2007 Primary Sjogren syndrome complicated by autoimmune hemolytic anemia and pure red cell aplasia.
Am. J. Med. Sci. 334: 493-496.
-
Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M 2007 Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: retrospective study.
Biomed. Pharmacother. 61: 370-376.
-
Atabek ME, Pirgon O 2007 Unusual cardiac features in cholestatic hepatitis A in an adolescent: improvement with corticosteroid treatment.
J. Infect. 54: e91-e93.
-
Atchia II, Kidd CE, Bell RW 2006 Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab.
J. Clin. Rheumatol. 12: 291-293.
-
Attwood SE, Lewis CJ, Bronder CS, Morris CD, Armstrong GR, Whittam J 2003 Eosinophilic oesophagitis: a novel treatment using Montelukast.
Gut 52: 181-185.
*
-
Au WY, Kwong YL 2008 Arsenic trioxide: safety issues and their management.
Acta Pharmacol. Sin. 29: 296-304.
-
Aubart FC, Ouayoun M, Brauner M, Attali P, Kambouchner M, Valeyre D, Nunes H 2006 Sinonasal involvement in sarcoidosis: a case-control study of 20 patients.
Medicine (Baltimore) 85: 365-371.
-
Auth MK, Kim HS, Beste M, Bonzel KE, Baumann U, Ballauff A, Wallot M, Borchers T, Vester U, Grasemann C, Hauffa B, Hoyer PF, Gerken G, Voit T 2005 Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children.
J. Pediatr. Gastroenterol. Nutr. 40: 54-59.
*
-
Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, Giese T, Loffler T, Buchler MW, Schmidt J 2005 High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease.
Gut 54: 944-949.
*
-
Auwardt RB, Mudge SJ, Chen CG, Power DA 1998 Regulation of nuclear factor kappaB by corticosteroids in rat mesangial cells.
J. Am. Soc. Nephrol. 9: 1620-1628.
-
Awada H, Abi-Karam G, Fayad F 2003 Musculoskeletal and other extrapulmonary disorders in sarcoidosis.
Best Pract. Res. Clin. Rheumatol. 17: 971-987.
-
Aydogan K, Karadogan SK, Adim SB, Tunali S 2006 Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus.
Int. J. Dermatol. 45: 1057-1061.
*
-
Azeroual A, Benomar A, Harmouche H, Daoudi N, Ait Benhaddou EH, Yahyaoui M, Maaouni A 2007 Primary Gougerot-Sjogren's syndrome presenting as a cerebellar syndrome.
Rev. Neurol. (Paris) 163: 1242-1245.
-
Azulay JP 2006 The diagnosis of chronic axonal polyneuropathy: the poorly understood chronic polyradiculoneuritides.
Rev. Neurol. (Paris) 162: 1292-1295.
-
Bachmeyer C, Leclerc-Landgraf N, Laurette F, Coutarel P, Cadranel JF, Medioni J, Dhote R, Mougeot-Martin M 1998 Acute autoimmune sensorineural hearing loss associated with Crohn's disease.
Am. J. Gastroenterol. 93: 2565-2567.
*
-
Badelon I 1999 Eye and spondylarthropathies.
Rev. Prat. 49: 1995-1998.
-
Bae SH, Kim JS, Kim DH 2006 Deflazacort for type-1 autoimmune hepatitis in a Korean girl.
J. Korean Med. Sci. 21: 758-760.
*
-
Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, Porta G, Nishioka M, Simon T, Daehnrich C, Schlumberger W, Galle PR, Lohse AW 2002 Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.
Gut 51: 259-264.
*
-
Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P 2004 Management of ulcerative colitis and Crohn's disease.
Acta Clin. Belg. 59: 304-314.
-
Bahadori HR, Williams VC, Turner RP, Rumboldt Z, Reigart JR, Fowler SL, Chavis PS, Maria BL 2007 Acute disseminated encephalomyelitis following infectious mononucleosis.
J. Child. Neurol. 22: 324-328.
-
Baker K, Jewell DP 1989 Cyclosporin for the treatment of severe inflammatory bowel disease.
Aliment. Pharmacol. Ther. 3: 143-149.
-
Balfour-Lynn IM 2007 Anti-inflammatory approaches to cystic fibrosis airways disease.
Curr. Opin. Pulm. Med. 13: 522-528.
-
Balzola FA, Khan K, Pera A, Bonino F, Pounder RE, Wakefield AJ 1998 Measles IgM immunoreactivity in patients with inflammatory bowel disease.
Ital. J. Gastroenterol. Hepatol. 30: 378-382.
-
Banerjee S, Bishop WP 2006 Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center: role of thiopurine methyltransferase and 6-mercaptopurine metabolite measurements.
J. Pediatr. Gastroenterol. Nutr. 43: 324-330.
*
-
Banerjee S, Rahhal R, Bishop WP 2006 Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis.
J. Pediatr. Gastroenterol. Nutr. 43: 353-356.
*
-
Bankhurst AD, Nunez SE, Draeger HT, Kettwich SC, Kettwich LG, Sibbitt WL Jr 2007 A randomized controlled trial of the reciprocating procedure device for intraarticular injection of corticosteroid.
J. Rheumatol. 34: 187-192.
-
Bannwarth B 2007 Drug-induced musculoskeletal disorders.
Drug Saf. 30: 27-46.
-
Barnes DS 2002 Intrahepatic cholestatic liver disease.
http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm.
-
Barnett B, Kruse-Jarres R, Leissinger CA 2008 Current management of acquired factor VIII inhibitors.
Curr. Opin. Hematol. 15: 451-455.
-
Barritt AS 4th, Zacks SL, Rubinas TC, Herfarth HH 2008 Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature.
Inflamm. Bowel Dis. Jul 10 [Epub ahead of print].
-
Barry PJ, Waterhouse DF, Reilly CM, McKenna TJ, McKone EF, Gallagher CG 2008 Androgens, exercise capacity and muscle function in cystic fibrosis.
Chest Aug 8 [Epub ahead of print].
-
Barth C, Bosse A, Andus T 2005 Severe acute cholestatic hepatitis by infiltration of monoclonal plasma cells in multiple myeloma.
Z. Gastroenterol. 43: 1129-1132.
-
Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP 2006 Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease.
World J. Gastroenterol. 12: 5680-5686.
*
-
Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J 2005 Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease.
Aliment. Pharmacol. Ther. 22: 775-782.
*
-
Bataller R, Brenner DA 2001 Hepatic stellate cells as a target for the treatment of liver fibrosis.
Semin. Liver Dis. 21: 437-451.
-
Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM 2008 Severe ulcerative colitis: present medical treatment strategies.
Expert Opin. Pharmacother. 9: 447-457.
-
Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S 1997 Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.
Gut 40: 470-474.
*
-
Baughman RP, Iannuzzi M 2003 Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
BioDrugs 17: 425-431.
-
Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber FL Jr 2003 Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis.
Arch. Intern. Med. 163: 615-620.
*
-
Baughman RP, Lower EE, du Bois RM 2003 Sarcoidosis.
Lancet 361: 1111-1118.
*
-
Baumgart DC, Macdonald JK, Feagan B 2008 Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis.
Cochrane Database Syst. Rev. 3: CD007216.
*
-
Baumgart DC, Sandborn WJ 2007 Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Lancet 369: 1641-1657.
*
-
Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R 2007 The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus.
J. Rheumatol. 34: 346-352.
-
Beattie RM 2005 Enteral nutrition as primary therapy in childhood Crohn's disease: control of intestinal inflammation and anabolic response.
JPEN J. Parenter. Enteral Nutr. 29: S151-S159.
*
-
Bebb JR, Scott BB 2004 How effective are the usual treatments for ulcerative colitis?
Aliment. Pharmacol. Ther. 20: 143-149.
*
-
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC 2006 Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
J. Clin. Oncol. 24: 2283-2289.
*
-
Becker H, Gaubitz M, Domschke W, Kucharzik T 2006 Joint involvement in chronic inflammatory bowel disease - current diagnostics and treatment options.
Z. Gastroenterol. 44: 497-502.
-
Becker H, Weber C, Storch S, Federlin K 1990 Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity.
Clin. Immunol. Immunopathol. 56: 219-225.
-
Beddy D, Watson RW, Fitzpatrick JM, O'Connell PR 2004 Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease.
Br. J. Surg. 91: 72-77.
*
-
Behm B, Bickston S 2008 Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn's disease.
Cochrane Database Syst. Rev. 1: CD006893.
*
-
Beishuizen A, van Bodegraven AA, Bronsveld W, Sindram JW 1993 Eosinophilic gastroenteritis - a disease with a wide clinical spectrum.
Neth. J. Med. 42: 212-217.
-
Beji S, Kaaroud H, Ben Moussa F, Goucha R, Abderrahim E, El Younsi F, Ben Maiz H 2004 Renal amyloidosis complicating the outcome of chronic inflammatory colitis.
Presse. Med. 33: 862-865.
-
Belda A, Hinojosa J, Serra B, Garcia L, Merino C, Belda A, Moles JR 2004 Systemic candidiasis and infliximab therapy.
Gastroenterol. Hepatol. 27: 365-367.
-
Bello C, Goldstein F, Thornton JJ 1991 Alternate-day prednisone treatment and treatment maintenance in Crohn's disease.
Am. J. Gastroenterol. 86: 460-466.
-
Belmont HM 2006 Treatment of ANCA-associated systemic vasculitis.
Bull. Hosp. Jt. Dis. 64: 60-66.
*
-
Beltinger J, Froehlich F 2005 Patients with inflammatory bowel disease in specialist gastroenterology practice: a prospective survey.
Schweiz. Rundsch. Med. Prax. 94: 459-465.
-
Ben Lagha N, Poulesquen V, Roujeau JC, Alantar A, Maman L 2005 Pemphigus vulgaris: a case-based update.
J. Can. Dent. Assoc. 71: 667-672.
-
Ben Rhouma K, Tebourbi O, Sakly M 2000 Acute hepatotoxicity of DDT: effect on glucocorticoid receptors and serum transcortin.
Indian J. Exp. Biol. 38: 452-456.
-
Ben-Horin S, Barshack I, Chowers Y, Mouallem M 2008 Flare-up of ulcerative colitis after systemic corticosteroids: a strong case for Strongyloides.
World J. Gastroenterol. 14: 4413-4415.
*
-
Benchimol E, Seow Ch, Steinhart A, Griffiths A 2008 Traditional corticosteroids for induction of remission in Crohn's disease.
Cochrane Database Syst. Rev. 2: CD006792.
*
-
Benchimol EI, Turner D, Mann EH, Thomas KE, Gomes T, McLernon RA, Griffiths AM 2008 Toxic megacolon in children with inflammatory bowel disease: clinical and radiographic characteristics.
Am. J. Gastroenterol. 103: 1524-1531.
*
-
Bergheim I, McClain CJ, Arteel GE 2005 Treatment of alcoholic liver disease.
Dig. Dis. 23: 275-284.
-
Bermejo F, Lopez-Sanroman A, Hinojosa J, Castro L, Jurado C, Gomez-Beldal AB 2004 Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis.
Rev. Esp. Enferm. Dig. 96: 94-101.
-
Bernatsky S, Lee JL, Rahme E 2007 Non-Hodgkin's lymphoma - meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories.
Rheumatology (Oxford) 46: 690-694.
*
-
Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, D'Armiento F, Romeo EF, Cucchiara S 2006 Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease.
Dig. Liver Dis. 38: 381-387.
-
Bernstein CN 2002 Treatment of the extraintestinal manifestations of inflammatory bowel disease.
Curr. Gastroenterol. Rep. 4: 513-516.
-
Bernstein CN 2006 Neoplasia in inflammatory bowel disease: surveillance and management strategies.
Curr. Gastroenterol. Rep. 8: 513-518.
-
Bernstein CN, Leslie WD 2004 Osteoporosis and inflammatory bowel disease.
Aliment. Pharmacol. Ther. 19: 941-952.
*
-
Bernstein CN, Leslie WD 2005 Therapy insight: osteoporosis in inflammatory bowel disease - advances and retreats.
Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 232-239.
*
-
Bernstein CN, Sargent M, Leslie WD 2005 Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
Inflamm. Bowel Dis. 11: 325-330.
*
-
Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F 1996 A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study.
Aliment. Pharmacol. Ther. 10: 777-786.
-
Bernstein M, Irwin S, Greenberg GR 2005 Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease.
Am. J. Gastroenterol. 100: 2031-2035.
*
-
Berti S, Amato L, Chiarini C, Fabbri P 2005 Case study: an itching and excoriated dermatosis during intrahepatic cholestasis of pregnancy.
Skinmed. 4: 248-249.
-
Beuers U, Rust C 2005 Overlap syndromes.
Semin. Liver Dis. 25: 311-320.
-
Bhat G, Jordan J Jr, Sokalski S, Bajaj V, Marshall R, Berkelhammer C 1998 Minocycline-induced hepatitis with autoimmune features and neutropenia.
J. Clin. Gastroenterol. 27: 74-75.
-
Bhat RM 2004 Management of pyoderma gangrenosum - an update.
Indian J. Dermatol. Venereol. Leprol. 70: 329-335.
-
Bianchi L, Terracciano LM 1994 Giant cell hepatitis in adults.
Schweiz. Rundsch. Med. Prax. 83: 1237-1241.
-
Bianchi ML 2005 How to manage osteoporosis in children.
Best Pract. Res. Clin. Rheumatol. 19: 991-1005.
-
Bickston SJ, Comerford LW, Cominelli F 2003 Future therapies for inflammatory bowel disease.
Curr. Gastroenterol. Rep. 5: 518-523.
-
Bilic M, Bumber Z, Blagaic AB, Batelja L, Seiwerth S, Sikiric P 2005 The stable gastric pentadecapeptide BPC 157, given locally, improves CO(2) laser healing in mice.
Burns 31: 310-315.
-
Billingsley GD, Walter MA, Hammond GL, Cox DW 1993 Physical mapping of four serpin genes: alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome I4q32.1.
Am. J. Hum. Genet. 52: 343-353.
*
-
Birand B, Cabre P, Bonnan M, Olindo S, Smadja D 2006 A new case of cerebellar ataxia with anti-GAD antibodies treated with corticosteroids and initially seronegative.
Rev. Med. Interne. 27: 616-619.
-
Biro T, Griger Z, Kiss E, Papp H, Aleksza M, Kovacs I, Zeher M, Bodolay E, Csepany T, Szucs K, Gergely P, Kovacs L, Szegedi G, Sipka S 2004 Abnormal cell-specific expressions of certain protein kinase C isoenzymes in peripheral mononuclear cells of patients with systemic lupus erythematosus: effect of corticosteroid application.
Scand. J. Immunol. 60: 421-428.
*
-
Bissuel F, Bizollon T, Dijoud F, Bouletreau P, Cordier JF, Chazot C, Gouillat C, Trepo C 1992 Pulmonary hemorrhage and glomerulonephritis in primary biliary cirrhosis.
Hepatology 16: 1357-1361.
-
Bittar F, Reynaud-Gaubert M, Thomas P, Boniface S, Raoult D, Rolain JM 2008 Acetobacter indonesiensis pneumonia after lung transplant.
Emerg. Infect. Dis. 14: 997-998.
*
-
Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C 1997 Reduced bone density in patients with inflammatory bowel disease.
Gut 40: 228-233.
*
-
Black M, Mignogna M, Scully C 2005 Pemphigus vulgaris.
Oral Dis. 11: 119-130.
*
-
Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, Rothenberg ME 2007 IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids.
J. Allergy Clin. Immunol. 120: 1292-1300.
*
-
Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsoe B, Torp-Pedersen S 2006 A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Scand. J. Rheumatol. 35: 341-345.
*
-
Blonski W, Lichtenstein GR 2006 Safety of biologics in inflammatory bowel disease.
Curr. Treat. Options Gastroenterol. 9: 221-233.
-
Blonski W, Lichtenstein GR 2007 Safety of biologic therapy.
Inflamm. Bowel Dis. 13: 769-796.
*
-
Blumenstein I, Bock H, Weber C, Rambow A, Tacke W, Kihn R, Pfaff R, Orlemann S, Schaeffer R, Schroder O, DignaB A, Hartmann F, Stein J 2008 Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study.
Inflamm. Bowel Dis. 14: 53-60.
-
Boberg KM, Egeland T, Schrumpf E 2003 Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients.
Scand. J. Gastroenterol. 38: 991-995.
*
-
Bockelmann R, Horn T, Gollnick H, Bonnekoh B 2005 Interferon-gamma-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects.
Skin Pharmacol. Physiol. 18: 42-54.
-
Bodger K 2005 Economic implications of biological therapies for Crohn's disease: review of infliximab.
Pharmacoeconomics 23: 875-888.
-
Bogdanos D, Vergani D, Mieli-Vergani G 2004 Overlap syndromes from pediatrics to adulthood.
J. Gastroenterol. Hepatol. 19: S284-S286. *
-
Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP 2005 Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
Liver Transpl. 11: 61-67.
*
-
Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, Belaiche J, Cadiot G, Metman EH, Cortot A, Colombel JF; Getaid 2003 Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.
Aliment. Pharmacol. Ther. 18: 401-408.
*
-
Bonfioli AA, Damico FM, Curi AL, Orefice F 2005 Intermediate uveitis.
Semin. Ophthalmol. 20: 147-154.
-
Bonfioli AA, de Miranda SS, Campos WR, Orefice F 2005 Tuberculosis.
Semin. Ophthalmol. 20: 169-175.
-
Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, Picard V 2004 MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients.
Transplantation 78: 21-25.
-
Bonnel AS, Quinque K, Le Roux P, Le Luyer B 2006 Semi-invasive necrotic aspergillosis in a child with cystic fibrosis.
Rev. Mal. Respir. 23: 343-347.
-
Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M 2008 Vitamin D deficiency in patients with active systemic lupus erythematosus.
Osteoporos. Int. Jul 4 [Epub ahead of print].
-
Borchers AT, Keen CL, Gershwin ME 2003 Use and misuse of corticosteroids.
Compr. Ther. 29: 157-165.
-
Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME 2004 Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus.
Autoimmun. Rev. 3: 423-453.
-
Borgaonkar M, MacIntosh D, Fardy J, Simms L 2000 Anti-tuberculous therapy for maintaining remission of Crohn's disease.
Cochrane Database Syst. Rev. 2: CD000299.
*
-
Borgaonkar MR, MacIntosh DG, Fardy JM 2000 A meta-analysis of antimycobacterial therapy for Crohn's disease.
Am. J. Gastroenterol. 95: 725-729.
*
-
Borgmann S, Endisch G, Urban S, Sitter T, Fricke H 2001 A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis.
Clin. Immunol. 98: 244-248.
*
-
Borkje B, Vetvik K, Odegaard S, Schrumpf E, Larssen TB, Kolmannskog F 1985 Chronic pancreatitis in patients with sclerosing cholangitis and ulcerative colitis.
Scand. J. Gastroenterol. 20: 539-542.
-
Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S 2004 Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Dig. Liver Dis. 36: 342-347.
-
Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S 2006 Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial.
Clin. Gastroenterol. Hepatol. 4: 744-753.
-
Bosch X 1998 Hypercalcemia due to endogenous overproduction of 1,25-dihydroxyvitamin D in Crohn's disease.
Gastroenterology 114: 1061-1065.
*
-
Bosch X, Guilabert A 2006 Kikuchi-Fujimoto disease.
Orphanet J. Rare Dis. 1: 18.
*
-
Botoman VA, Bonner GF, Botoman DA 1998 Management of inflammatory bowel disease.
Am. Fam. Physician 57: 57-68, 71-72.
-
Boumpas DT, Sidiropoulos P, Bertsias G 2005 Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?
Nat. Clin. Pract. Rheumatol. 1: 22-30.
*
-
Bourges O, Dorgeret S, Alberti C, Hugot JP, Sebag G, Cezard JP 2004 Low bone mineral density in children with Crohn's disease.
Arch. Pediatr. 11: 800-806.
-
Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL 2005 A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease.
Inflamm. Bowel Dis. 11: 833-839.
*
-
Bovenschen HJ, Gerritsen WJ, van Rens DW, Seyger MM, de Jong EM, van de Kerkhof PC 2007 Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
Arch. Dermatol. Res. 298: 457-463.
*
-
Boyd AS 2006 Localized chronic cutaneous lupus erythematosus masquerading as pigmented lesions: a new clinical subset?
Lupus 15: 292-295.
-
Boyer JL 2005 Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?
Gastroenterology 129: 735-740.
*
-
Braegger CP, Torresani T, Murch SH, Savage MO, Walker-Smith JA, MacDonald TT 1993 Urinary growth hormone in growth-impaired children with chronic inflammatory bowel disease.
J. Pediatr. Gastroenterol. Nutr. 16: 49-52.
-
Brailski Kh, Damianov B 1983 Primary biliary cirrhosis.
Vutr. Boles. 22: 27-37.
-
Brandsaeter B, Schrumpf E, Clausen OP, Abildgaard A, Hafsahl G, Bjoro K 2004 Recurrent sclerosing cholangitis or ischemic bile duct lesions - a diagnostic challenge?
Liver Transpl. 10: 1073-1074.
*
-
Brandt D, Gershwin ME 2006 Common variable immune deficiency and autoimmunity.
Autoimmun. Rev. 5: 465-470.
-
Brandt J, Braun J 2006 Anti-TNF-alpha agents in the treatment of psoriatic arthritis.
Expert Opin. Biol. Ther. 6: 99-107.
-
Brar P, Lee S, Lewis S, Egbuna I, Bhagat G, Green PH 2007 Budesonide in the treatment of refractory celiac disease.
Am. J. Gastroenterol. 102: 2265-2269.
*
-
Braucci S, Trappolini F, Angrisani L, Luberti E, Clarice A, Proietta M, Pisani D, Trappolini M 2007 Ulcerative colitis and thrombocytopenia: a clinical case of fortuitous association?
Clin. Ter. 158: 27-30.
-
Bray GP, Williams R 1992 Immunointervention in primary biliary cirrhosis: an overview.
J. Autoimmun. 5 Suppl. A: 293-300.
-
Bremner AR, Beattie RM 2007 Recent advances in the medical therapy of Crohn's disease in childhood.
Expert Opin. Pharmacother. 8: 2553-2568.
-
Bremner AR, Griffiths DM, Beattie RM 2004 Current therapy of ulcerative colitis in children.
Expert Opin. Pharmacother. 5: 37-53.
-
Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A 2007 Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study.
Dig. Liver Dis. 39: 430-434.
-
Breuer A, Benz SR, Enz T, Deubler G, Mork H 2007 Autoimmune pancreatitis - a rare and difficult differential diagnosis to pancreatic cancer.
Med. Klin. (Munich) 102: 157-162.
-
Brightling C, Berry M, Amrani Y 2008 Targeting TNF-alpha: a novel therapeutic approach for asthma.
J. Allergy Clin. Immunol. 121: 5-10.
*
-
Brinckerhoff CE, Sporn MB 2003 Retinoids and rexinoids for the 21st century: a brave new world for arthritis.
J. Rheumatol. 30: 211-213.
-
Brogan PA, Malik M, Shah N, Kilday JP, Ramsay A, Shah V, Murch SH, Thomson MA, Walker-Smith JA, Lindley KJ, Milla PJ, Dillon MJ 2006 Systemic vasculitis: a cause of indeterminate intestinal inflammation.
J. Pediatr. Gastroenterol. Nutr. 42: 405-415.
*
-
Brookes MJ, Green JR 2004 Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
Drugs 64: 1069-1089.
-
Broughton SS, Meyerhoff WE, Cohen SB 2004 Immune-mediated inner ear disease: 10-year experience.
Semin. Arthritis Rheum. 34: 544-548.
*
-
Brucato A, Maestroni S, Cumetti D, Thiella G, Alari G, Brambilla G, Imazio M, Doria A, Palmieri G, Adler Y 2008 Recurrent pericarditis: infectious or autoimmune?
Autoimmun. Rev. Aug 12 [Epub ahead of print].
-
Brunner HI, Kim KN, Ballinger SH, Bowyer SL, Griffin TA, Higgins GC, Mier R, Passo MH, Rennebohm R, Schikler K, Lovell DJ 2001 Current medication choices in juvenile rheumatoid arthritis II - update of a survey performed in 1993.
J. Clin. Rheumatol. 7: 295-300.
-
Brunner M, Greinix HT, Redlich K, Knobl P, Smolen J, Leitner G, Derfler K, Graninger W, Kalhs P, Machold K 2002 Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report.
Arthritis Rheum. 46: 1580-1584.
*
-
Brunt EM, Di Bisceglie AM 2004 Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis.
Hum. Pathol. 35: 509-512.
-
Brydak-Godowska J, Moneta-Wielgos J, Pauk-Domanska M, Drobecka-Brydak E, Samsel A, Kecik M, Kowalewski C, Mackiewicz W, Kecik D 2005 Diagnostics and farmacological treatment of ocular cicatrical pemphigoid.
Klin. Oczna. 107: 725-727.
-
Brynskov J, Feagan BG, Jewell D, McDonald JWD, Stange EF 2004 Cyclosporine for maintenance of remission in Crohn’s disease.
Cochrane Database Syst. Rev. 2: CD004377. *
-
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M, Font J, Asherson RA 2006 Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.
Arthritis Rheum. 54: 2568-2576.
*
-
Buchman AL 1999 Bones and Crohn's: problems and solutions.
Inflamm. Bowel Dis. 5: 212-227.
-
Buchman AL 2002 Metabolic bone disease in inflammatory bowel disease.
Curr. Treat. Options Gastroenterol. 5: 173-180.
-
Buchman AL, Paine MF, Wallin A, Ludington SS 2005 A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content.
Dig. Dis. Sci. 50: 2312-2315.
*
-
Budimir J, Mihic LL, Situm M, Bulat V, Persic S, Tomljanovic-Veselski M 2008 Oral lesions in patients with pemphigus vulgaris and bullous pemphigoid.
Acta Clin. Croat. 47: 13-18.
-
Bueverov AO 2004 Treatment of autoimmune hepatic diseases.
Klin. Med. (Mosk.) 82: 62-66.
-
Buhaescu I, Covic A, Deray G 2007 Treatment of proliferative lupus nephritis - a critical approach.
Semin. Arthritis Rheum. 36: 224-237.
*
-
Buning C, Lochs H 2006 Conventional therapy for Crohn's disease.
World J. Gastroenterol. 12: 4794-4806.
*
-
Burak KW, Angulo P, Lindor KD 2003 Is there a role for liver biopsy in primary sclerosing cholangitis?
Am. J. Gastroenterol. 98: 1155-1158.
*
-
Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G, Vermeire S, Rutgeerts P, D'Hoore A, Penninckx F, Geboes K, Van Assche G, O'Connell PR 2008 Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease.
Inflamm. Bowel Dis. 14: 1197-1204.
*
-
Burns TM 2003 Neurosarcoidosis.
Arch. Neurol. 60: 1166-1168.
-
Burt AD 2004 Spectrum of liver pathology in immune mediated liver diseases.
J. Gastroenterol. Hepatol. 19: S353-S355. *
-
Bystryn JC, Rudolph JL 2005 Pemphigus.
Lancet 366: 61-73.
*
-
Byth BC, Billingsley GD, Cox DW 1994 Physical and genetic mapping of the serpin gene cluster at 14q32.1: allelic association and a unique haplotype associated with alpha 1-antitrypsin deficiency.
Am. J. Hum. Genet. 55: 126-133.
*
-
Caballero-Uribe CV, Acosta-Velez JG, Hernandez-Ruiz EA, Andrade Rodado FM, Penuela-Epalza M 2008 Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city.
J. Clin. Rheumatol. 14: 153-155.
-
Cabo-Lopez I, Negueruela-Lopez M, Garcia-Bermejo P, Zamarbide-Capdepon I, Garcia-Ruiz PJ, Duran-Martinez P, Gonzalez-Roiz C 2008 Stiff-person syndrome: a case report.
Rev. Neurol. 47: 249-252.
-
Cagatay AA, Taranoglu O, Alpay N, Tufan F, Karadeniz A, Kapmaz M, Buyukbabani N 2008 Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.
Mycoses 51: 81-82.
-
Cakir E, Uyan ZS, Ersu RH, Karadag B, Karakoc F, Dagli E 2006 Mucoid impaction: an unusual form of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis.
Pediatr. Pulmonol. 41: 1103-1107.
-
Calder PC 2008 Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases.
Mol. Nutr. Food Res. 52: 885-897.
*
-
Callen JP 2005 Management of 'refractory' skin disease in patients with lupus erythematosus.
Best Pract. Res. Clin. Rheumatol. 19: 767-784.
-
Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, Poupon R 1992 Cholestasis induces major histocompatibility complex class I expression in hepatocytes.
Gastroenterology 102: 1371-1377.
-
Calmus Y, Poupon R 1991 Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases.
Biochimie 73: 1335-1338.
-
Campbell R, Marik PE 2005 Severe autoimmune hemolytic anemia treated by paralysis, induced hypothermia, and splenic embolization.
Chest 127: 678-681.
*
-
Campbell S, Ghosh S 2003 Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome.
Dig. Liver Dis. 35: 546-551.
-
Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kaplan M, Wright F, Kam I 2008 Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal.
Liver Transpl. 14: 1281-1286.
-
Cappell MS, Turkieh A 2008 Chronic pericarditis and pericardial tamponade associated with ulcerative colitis.
Dig. Dis. Sci. 53: 149-154.
*
-
Caprilli R, Viscido A, Guagnozzi D 2002 Review article: biological agents in the treatment of Crohn's disease.
Aliment. Pharmacol. Ther. 16: 1579-1590.
*
-
Carbone J, Escudero A, Mayayo M, Ballesteros M, Perez-Corral A, Sanchez-Ramon S, Sarmiento E, Micheloud D, Fernandez-Cruz E 2005 Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
Ann. N. Y. Acad. Sci. 1051: 666-671.
-
Carbonnel F 2007 Management of severe or corticosteroid resistant ulcerative colitis.
Gastroenterol. Clin. Biol. 31: 398-403.
-
Carcagni MR, De Aloe G, D'Ascenzo G, Rubegni P, Fimiani M 2008 Extracorporeal photopheresis in graft-versus-host disease.
J. Dtsch. Dermatol. Ges. 6: 451-457.
-
Card T, West J, Hubbard R, Logan RF 2004 Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study.
Gut 53: 251-255.
*
-
Carette S 2007 All patients with rheumatoid arthritis should receive corticosteroids as part of their management.
J. Rheumatol. 34: 656-660.
-
Carrillo-Esper R, Gonzalez-Avila D, Uribe-Rios M, Mendez-Sanchez N 2008 Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report.
Ann. Hepatol. 7: 87-90.
-
Carvalho R, Hyams JS 2007 Diagnosis and management of inflammatory bowel disease in children.
Semin. Pediatr. Surg. 16: 164-171.
-
Castiblanco CP, Adelman RA 2008 Sympathetic ophthalmia.
Graefes. Arch. Clin. Exp. Ophthalmol. Sep 16 [Epub ahead of print].
-
Castro Junior NP, Almeida CI, Campos CA 2007 Sudden sensorineural hearing loss and vertigo associated with arterial occlusive disease: three case reports and literature review.
Sao Paulo Med. J. 125: 191-195.
*
-
Castro M, Papadatou B, Ceriati E, Knafelz D, De Angelis P, Ferretti F, Gambarara M, Diamanti A, De Peppo F, Rivosecchi M 2007 Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis.
Langenbecks Arch. Surg. 392: 161-164.
*
-
Cauley JA 2006 Osteoporosis in men: prevalence and investigation.
Clin. Cornerstone 8 Suppl. 3: S20-S25.
-
Cavailhes A, Ingen-Housz-Oro S, Djennane S, Rafaa M, Fiszenson-Albala F, Weber N, Sigal-Grinberg M 2007 Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab.
Ann. Dermatol. Venereol. 134: 363-367.
-
Cazanave C, Rakotondravelo S, Morlat P, Blanco P, Bonnet F, Beylot J 2006 Autoimmune hepatitis in a HIV-HCV co-infected patient: diagnostic and therapeutic difficulties.
Rev. Med. Interne. 27: 414-419.
-
Ceovic R, Pasic A, Lipozencic J, Murat-Susic S, Skerlev M, Husar K, Kostovic K 2006 Treatment of childhood psoriasis.
Acta Dermatovenerol. Croat. 14: 261-264.
-
Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, Mougenot JF, Alberti C, Goulet O 2003 A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease.
J. Pediatr. Gastroenterol. Nutr. 36: 632-636.
*
-
Cha SI, Fessler MB, Cool CD, Schwarz MI, Brown KK 2006 Lymphoid interstitial pneumonia: clinical features, associations, and prognosis.
Eur. Respir. J. 28: 364-369.
-
Chaby G, Viseux V, Poulain JF, De Cagny B, Denoeux JP, Lok C 2005 Topical silver sulfadiazine-induced acute renal failure.
Ann. Dermatol. Venereol. 132: 891-893.
-
Chambers SA, Isenberg D 2005 Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.
Lupus 14: 210-214.
-
Chan EP, Lichtenstein GR 2006 Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
Gastroenterol. Clin. North Am. 35: 675-712.
-
Chan TM 2005 Lupus nephritis: induction therapy.
Lupus 14 Suppl. 1: s27-s32.
-
Chan YC, Tay YK, Ng SK 2002 Allopurinol hypersensitivity syndrome and acute myocardial infarction - two case reports.
Ann. Acad. Med. Singapore 31: 231-233.
*
-
Chande N 2008 Microscopic colitis: an approach to treatment.
Can. J. Gastroenterol. 22: 686-688.
-
Chande N, Macdonald J, McDonald J 2007 Methotrexate for induction of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 4: CD006618.
-
Chande N, McDonald J, Macdonald J 2008 Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 2: CD006774.
*
-
Chang HK 2005 Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus.
J. Korean Med. Sci. 20: 883-885.
*
-
Chao SC, Yang CC, Lee JY 2005 Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease.
Ann. Pharmacother. 39: 1552-1556.
-
Chaoui Z, Bernoussi A, Belmekki M, Berraho A 2005 Uveitis and chronic intestinal inflammatory diseases: three case studies.
J. Fr. Ophtalmol. 28: 854-856.
-
Chapman RW 2003 The management of primary sclerosing cholangitis.
Curr. Gastroenterol. Rep. 5: 9-17.
-
Chaudhary R, Ghosh S 2005 Infliximab in refractory coeliac disease.
Eur. J. Gastroenterol. Hepatol. 17: 603-604.
-
Chavez-Tapia NC, Martinez-Salgado J, Granados J, Uribe M, Tellez-Avila FI 2007 Clinical heterogeneity in autoimmune acute liver failure.
World J. Gastroenterol. 13: 1824-1827.
*
-
Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R 1998 Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Hepatology 28: 296-301.
*
-
Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R 2006 Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
J. Hepatol. 44: 400-406.
*
-
Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF 2007 Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
J. Gastroenterol. Hepatol. 22: 268-274.
*
-
Chebli JM, Gaburri PD, Meirelles De Souza AF, Pereira Da Silva CE, Pinto JR, Felga GE 2004 Benign intracranial hypertension during corticosteroid therapy for idiopathic ulcerative colitis: another indication for cyclosporine?
J. Clin. Gastroenterol. 38: 827-828.
-
Cheifetz A, Itzkowitz S 2004 The diagnosis and treatment of pouchitis in inflammatory bowel disease.
J. Clin. Gastroenterol. 38: S44-S50.
-
Chen J, Wang Y, Kunkel G, Zhao H, Xue H, Xie X, Li L, Xu C, Shen L, Gu L 2005 Use of CD34(+) autologous stem cell transplantation in the treatment of children with refractory systemic lupus erythematosus.
Clin. Rheumatol. 24: 464-468.
*
-
Chen M, Yu F, Zhang Y, Zhao MH 2005 An analysis of multi-system involvement and renal pathology of anti-neutrophil cytoplasmic autoantibodies-related vasculitis.
Zhonghua Nei Ke Za Zhi 44: 828-831.
-
Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE 2003 Eosinophilic gastroenteritis: clinical experience with 15 patients.
World J. Gastroenterol. 9: 2813-2816.
*
-
Chen WD, Gluud C 2004 Glucocorticosteroids for primary sclerosing cholangitis.
Cochrane Database Syst. Rev. 3: CD004036.
*
-
Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Lazzell-Pannell L, Rashdan A, Temkit M, Lehman GA 2006 Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Am. J. Gastroenterol. 101: 139-147.
*
-
Chernev K, Bakalov V 1985 Clinical-dispensary finding of patients with primary biliary cirrhosis.
Vutr. Boles. 24: 42-46.
-
Chey WY 2001 Infliximab for patients with refractory ulcerative colitis.
Inflamm. Bowel Dis. 7 Suppl. 1: S30-S33.
*
-
Chikanza IC, Kozaci D, Chernajovsky Y 2003 The molecular and cellular basis of corticosteroid resistance.
J. Endocrinol. 179: 301-310.
*
-
Chinratanapisit S, Tunsuriyawong P, Vichyanond P, Visitsunthorn N, Luangwedchakarn V, Jirapongsananuruk O 2005 Chronic rhinosinusitis and recurrent nasal polyps in two children with IgG subclass deficiency and review of the literature.
J. Med. Assoc. Thai. 88 Suppl. 8: S251-S258.
-
Chitturi S, Farrell GC 2000 Drug-induced liver disease.
Curr. Treat. Options Gastroenterol. 3: 457-462.
-
Cho J 2000 Update on inflammatory bowel disease genetics.
Curr. Gastroenterol. Rep. 2: 434-439.
-
Choi EK, Kim MH, Kim JC, Han J, Oh SI, Jeong WJ, Jeong JY, Lee SS, Seo DW, Lee SK 2006 The long-term follow-up results after steroid treatment in patients with autoimmune chronic pancreatitis.
Korean J. Gastroenterol. 47: 440-448.
-
Chon CY, Park JY 2006 Primary biliary cirrhosis.
Korean J. Hepatol. 12: 364-372.
-
Chrissafidou A, Malek M, Musch E 2007 Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.
Z. Gastroenterol. 45: 605-608.
-
Christen-Zaech S, Hakim MD, Afsar FS, Paller AS 2008 Pediatric morphea (localized scleroderma): review of 136 patients.
J. Am. Acad. Dermatol. 59: 385-396.
-
Christensen E 2002 Alcoholic hepatitis - glucocorticosteroids or not?
J. Hepatol. 36: 547-548.
*
-
Christensen PS, Ostergaard JR 2008 Acute disseminated encephalomyelitis.
Ugeskr. Laeger. 170: 1839-1842.
-
Chugh S, Dilawari JB, Sawhney IM, Dang N, Radotra BD, Chawla YK 1993 Polymyositis associated with ulcerative colitis.
Gut 34: 567-569.
*
-
Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, Morgenstern EH, Rubin SD, Sacknoff AG, Gleim GM 1998 Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up.
Inflamm. Bowel Dis. 4: 177-181.
*
-
Chung CP, Avalos I, Raggi P, Stein CM 2007 Atherosclerosis and inflammation: insights from rheumatoid arthritis.
Clin. Rheumatol. 26: 1228-1233.
*
-
Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM 2007 Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.
J. Rheumatol. 34: 1849-1854.
-
Chung GE, Cheon JH, Lee JY, Ye BD, Kim SG, Kim JS, Jung HC, Song IS 2006 Efficacy of combination of intravenous cyclosporin A and steroid therapy versus prolonged intravenous steroid therapy alone in patients with severe ulcerative colitis refractory to initial intravenous steroid therapy.
Korean J. Gastroenterol. 48: 263-268.
-
Cicek D, Kandi B, Demir B, Turgut D 2007 Intrahepatic cholestasis occurring with prurigo of pregnancy.
Skinmed. 6: 298-301.
-
Clatworthy MR, Jayne DR 2006 Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab.
Am. J. Kidney Dis. 47: 680-682.
-
Claudepierre P, Bagot M 2008 Psoriatic arthritis.
Ann. Dermatol. Venereol. 135 Suppl. 4: S263-S268.
-
Claussmann C, Offner C, Chevalier Y, Sellal F, Collard M 1994 Encephalopathy and Hashimoto thyroiditis.
Rev. Neurol. (Paris) 150: 166-168.
-
Clegg-Lamptey JN, Tettey Y, Wiredu EK, Kwawukume EY 2002 Eosinophilic enteritis - a diagnostic dilemma.
West Afr. J. Med. 21: 258-259.
-
Cohen PR 2007 Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis.
Orphanet J. Rare Dis. 2: 34.
*
-
Cohen RD 2002 Evolving medical therapies for ulcerative colitis.
Curr. Gastroenterol. Rep. 4: 497-505.
-
Cohen RD 2001 Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Inflamm. Bowel Dis. 7 Suppl. 1: S17-S22.
*
-
Cohran VC, Heubi JE 2003 Treatment of pediatric cholestatic liver disease.
Curr. Treat. Options Gastroenterol. 6: 403-415.
-
Colbert C, Chavarria A, Berkelhammer C 2007 Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease.
Inflamm. Bowel Dis. 13: 1453-1454.
-
Cole BJ, Schumacher HR Jr 2005 Injectable corticosteroids in modern practice.
J. Am. Acad. Orthop. Surg. 13: 37-46.
-
Colmegna I, Maldonado-Cocco JA 2005 Polyarteritis nodosa revisited.
Curr. Rheumatol. Rep. 7: 288-296.
-
Colombato LA, Alvarez F, Cote J, Huet PM 1994 Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?
Gastroenterology 107: 1839-1843.
-
Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ 2004 Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Am. J. Gastroenterol. 99: 878-883.
*
-
Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ 2006 Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
J. Rheumatol. 33: 24-30.
-
Comite de nutrition de la Societe francaise de pediatrie 2005 Nutritional treatment in childhood Crohn's disease.
Arch. Pediatr. 12: 1255-1266.
-
Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED 2007 Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
Arthritis Rheum. 56: 1966-1973.
*
-
Connell W, Miller A 1999 Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy.
Drug Saf. 21: 311-323.
-
Conrad C, Trueb RM 2005 Pyoderma gangrenosum.
J. Dtsch. Dermatol. Ges. 3: 334-342.
-
Contreras G, Tozman E, Nahar N, Metz D 2005 Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Lupus 14 Suppl. 1: s33-s38.
-
Conway RR 2008 Neuralgic amyotrophy: uncommon but not rare.
Mo. Med. 105: 168-169.
-
Cooke DM 1991 Inflammatory bowel disease: primary health care management of ulcerative colitis and Crohn's disease.
Nurse Pract. 16: 27-30, 35-36, 38-39.
-
Copeland BH, Aramide O, Wehbe S, Fitzgerald SM, Krishnaswamy G 2004 Eosinophilia in a patient with cyclical vomiting: a case report.
Clin. Mol. Allergy 2: 7.
*
-
Cosme A, Gil I, Alvarez R, Ruiz I, de Juan MD, Ojeda E, Barrio J 1998 Autoimmune hepatitis with antibodies against liver cytosol (anti-LC1).
Gastroenterol. Hepatol. 21: 280-282.
-
Costa Carvalho BT, Nagao AT, Arslanian C, Carneiro Sampaio MM, Naspitz CK, Sorensen RU, Leiva L, Sole D 2005 Immunological evaluation of allergic respiratory children with recurrent sinusitis.
Pediatr. Allergy Immunol. 16: 534-538.
-
Costa M, Colia D 2008 Treating infertility in autoimmune patients.
Rheumatology (Oxford) 47 Suppl. 3: iii38-iii41.
-
Costabel U 2001 Sarcoidosis: clinical update.
Eur. Respir. J. Suppl. 32: 56s-68s.
*
-
Cotler SJ, Jakate S, Jensen DM 2001 Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy.
J. Clin. Gastroenterol. 32: 428-430.
-
Cox KL, Cox KM 1998 Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease.
J. Pediatr. Gastroenterol. Nutr. 27: 580-583.
-
Crabb DW 1993 Recent developments in alcoholism: the liver.
Recent Dev. Alcohol. 11: 207-230.
-
Cronstein BN, Terkeltaub R 2006 The inflammatory process of gout and its treatment.
Arthritis Res. Ther. 8 Suppl. 1: S3.
*
-
Cuadrado E, Alonso M, de Juan MD, Echaniz P, Arenas JI 2008 Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis.
World J. Gastroenterol. 14: 1521-1527.
*
-
Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, De'Angelis GL, Federici T 2008 Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study.
Dig. Liver Dis. 40 Suppl. 2: S260-S264.
-
Cuffari C 2006 Inflammatory bowel disease in children: a pediatrician's perspective.
Minerva Pediatr. 58: 139-157.
-
Cuffari C, Hunt S, Bayless T 2001 Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
Gut 48: 642-646.
*
-
Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B 2006 Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease.
Digestion 73: 107-110.
-
Cullen G, O'Toole A, Keegan D, Sheahan K, Hyland JM, O'Donoghue DP 2007 Long-term clinical results of ileocecal resection for Crohn's disease.
Inflamm. Bowel Dis. 13: 1369-1373.
-
Culver DA, Thomassen MJ, Kavuru MS 2004 Pulmonary sarcoidosis: new genetic clues and ongoing treatment controversies.
Cleve. Clin. J. Med. 71: 88, 90, 92.
*
-
Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH 2006 Estrogens and autoimmune diseases.
Ann. N. Y. Acad. Sci. 1089: 538-547.
*
-
Cutolo M, Villaggio B, Otsa K, Aakre O, Sulli A, Seriolo B 2005 Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms.
Autoimmun. Rev. 4: 497-502.
-
Czaja AJ 2002 Treatment strategies in autoimmune hepatitis.
Clin. Liver Dis. 6: 511-536.
-
Czaja AJ 2008 Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.
Drugs Aging 25: 219-239.
-
Czaja AJ 2006 Autoimmune hepatitis - approach to diagnosis.
MedGenMed. 8: 55.
-
Czaja AJ 2001 Autoimmune liver disease.
Curr. Opin. Gastroenterol. 17: 268-275.
-
Czaja AJ 1999 Autoimmune liver disease.
Curr. Opin. Gastroenterol. 15: 240-248.
-
Czaja AJ 1997 Extrahepatic immunologic features of chronic viral hepatitis.
Dig. Dis. 15: 125-144.
-
Czaja AJ 2003 The autoimmune hepatitis/hepatitis C overlap syndrome: does it exist?
Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 42-43. October 15-16. *
-
Czaja AJ 2004 Autoimmune liver disease.
Curr. Opin. Gastroenterol. 20: 231-240.
-
Czaja AJ 1996 The variant forms of autoimmune hepatitis.
Ann. Intern. Med. 125: 588-598.
-
Czaja AJ 1999 The immunoreactive propensity of autoimmune hepatitis: is it corticosteroid-dependent after liver transplantation?
Liver Transpl. Surg. 5: 460-463.
-
Czaja AJ 1994 Autoimmune hepatitis and viral infection.
Gastroenterol. Clin. North Am. 23: 547-566.
-
Czaja AJ 1981 Current problems in the diagnosis and management of chronic active hepatitis.
Mayo Clin. Proc. 56: 311-323.
-
Czaja AJ 2007 Autoimmune liver disease.
Curr. Opin. Gastroenterol. 23: 255-262.
-
Czaja AJ 2006 Autoimmune liver disease.
Curr. Opin. Gastroenterol. 22: 234-240.
-
Czaja AJ 2006 Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries.
J. Hepatol. 44: 251-252.
*
-
Czaja AJ 2007 Autoimmune liver disease and rheumatic manifestations.
Curr. Opin. Rheumatol. 19: 74-80.
-
Czaja AJ 2002 Treatment of autoimmune hepatitis.
Semin. Liver Dis. 22: 365-378.
*
-
Czaja AJ 2007 Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation.
Liver Transpl. 13: 953-955.
*
-
Czaja AJ 1990 Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis.
Hepatology 11: 1044-1049.
-
Czaja AJ 1998 Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis.
Dig. Dis. Sci. 43: 1725-1731.
*
-
Czaja AJ 1999 Drug therapy in the management of type 1 autoimmune hepatitis.
Drugs 57: 49-68.
-
Czaja AJ 2004 Round table: classification of autoimmune liver diseases and diagnostic criteria. Subgroups of autoimmune hepatitis are irrelevant.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 58-59. *
-
Czaja AJ 1999 Variant forms of autoimmune hepatitis.
Curr. Gastroenterol. Rep. 1: 63-70.
-
Czaja AJ 2002 Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance.
Liver Transpl. 8: 505-513.
*
-
Czaja AJ 2004 Autoimmune hepatitis: clinical and laboratory diagnosis.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 52-54. *
-
Czaja AJ 2005 Autoimmune liver disease.
Curr. Opin. Gastroenterol. 21: 293-299.
-
Czaja AJ 2008 Autoimmune liver disease.
Curr. Opin. Gastroenterol. 24: 298-305.
-
Czaja AJ 1998 Frequency and nature of the variant syndromes of autoimmune liver disease.
Hepatology 28: 360-365.
*
-
Czaja AJ, Abdulkarim AS, Carpenter HA, Perez RG, Persing DH, Zein NN 1998 GB virus-C infection in type 1 autoimmune hepatitis.
Mayo Clin. Proc. 73: 412-418.
-
Czaja AJ, Ammon HV, Summerskill WH 1980 Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission.
Gastroenterology 78: 518-523.
-
Czaja AJ, Beaver SJ, Shiels MT 1987 Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.
Gastroenterology 92: 215-219.
-
Czaja AJ, Beaver SJ, Wood JR, Klee GG, Go VL 1987 Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis.
Gastroenterology 93: 687-692.
-
Czaja AJ, Carpenter HA 2004 Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.
J. Hepatol. 40: 646-652.
*
-
Czaja AJ, Carpenter HA 2005 Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
J. Clin. Gastroenterol. 39: 819-825.
-
Czaja AJ, Carpenter HA 2006 Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly.
Hepatology 43: 532-538.
*
-
Czaja AJ, Carpenter HA 2004 Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis.
Hepatology 39: 1631-1638.
*
-
Czaja AJ, Carpenter HA 2003 Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis.
Liver Int. 23: 116-123.
*
-
Czaja AJ, Carpenter HA, Lindor KD 1999 Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.
Hepatology 30: 1381-1386.
*
-
Czaja AJ, Carpenter HA, Manns MP 1993 Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis.
Gastroenterology 105: 1522-1528.
-
Czaja AJ, Carpenter HA, Moore SB 2006 Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.
Liver Int. 26: 552-558.
*
-
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB 1993 Significance of HLA DR4 in type 1 autoimmune hepatitis.
Gastroenterology 105: 1502-1507.
-
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB 2000 Autoimmune cholangitis within the spectrum of autoimmune liver disease.
Hepatology 31: 1231-1238.
*
-
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA 1993 The nature and prognosis of severe cryptogenic chronic active hepatitis.
Gastroenterology 104: 1755-1761.
-
Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT 1999 Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis.
Gastroenterology 117: 645-652.
*
-
Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF 1983 Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology.
Gastroenterology 85: 713-717.
-
Czaja AJ, Davis GL, Ludwig J, Taswell HF 1984 Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis.
Hepatology 4: 622-627.
-
Czaja AJ, Hay JE, Rakela J 1990 Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis.
Mayo Clin. Proc. 65: 23-30.
-
Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A 1981 Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis.
N. Engl. J. Med. 304: 5-9.
-
Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L 1995 Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis.
Dig. Dis. Sci. 40: 33-40.
-
Czaja AJ, Manns MP, Homburger HA 1992 Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.
Gastroenterology 103: 1290-1295.
-
Czaja AJ, Menon KV, Carpenter HA 2002 Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
Hepatology 35: 890-897.
*
-
Czaja AJ, Ming C, Shirai M, Nishioka M 1995 Frequency and significance of antibodies to histones in autoimmune hepatitis.
J. Hepatol. 23: 32-38.
*
-
Czaja AJ, Morshed SA, Parveen S, Nishioka M 1997 Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis.
Hepatology 26: 567-572.
*
-
Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB 2004 Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis.
Liver Int. 24: 322-329.
*
-
Czaja AJ, Pfeifer KD, Decker RH, Vallari AS 1996 Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis.
Dig. Dis. Sci. 41: 1733-1740.
-
Czaja AJ, Rakela J, Hay JE, Moore SB 1990 Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis.
Gastroenterology 98: 1587-1593.
-
Czaja AJ, Rakela J, Ludwig J 1988 Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis.
Gastroenterology 95: 448-453.
-
Czaja AJ, Shiels MT, Taswell HF, Wood JR, Ludwig J, Chase RC 1988 Frequency and significance of immunoglobulin M antibody to hepatitis B core antigen in corticosteroid-treated severe chronic active hepatitis B.
Mayo Clin. Proc. 63: 119-125.
-
Czaja AJ, Shums Z, Donaldson PT, Norman GL 2004 Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis.
Dig. Dis. Sci. 49: 611-618.
*
-
Czaja AJ, Shums Z, Norman GL 2002 Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis.
Autoimmunity 35: 475-483.
-
Czaja AJ, Sievers C, Zein NN 2000 Nature and behavior of serum cytokines in type 1 autoimmune hepatitis.
Dig. Dis. Sci. 45: 1028-1035.
*
-
Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R 1997 Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.
Hepatology 25: 317-323.
*
-
Czaja AJ, Taswell HF, Rakela J, Rabe D 1992 Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis.
Gastroenterology 102: 1675-1679.
-
Czaja AJ, Taswell HF, Rakela J, Schimek CM 1991 Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis.
Mayo Clin. Proc. 66: 572-582.
-
Czaja AJ, Taswell HF, Rakela J, Schimek CM 1990 Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated cryptogenic chronic active hepatitis.
Mayo Clin. Proc. 65: 1303-1313.
-
Czaja AJ, Wang KK, Shiels MT, Katzmann JA 1993 Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses.
J. Hepatol. 17: 180-186.
-
Czaja AJ, Wolf AM, Baggenstoss AH 1981 Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features.
Gastroenterology 80: 687-692.
-
D'Amato G, Salzillo A, Piccolo A, D'Amato M, Liccardi G 2007 A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
Ther. Clin. Risk Manag. 3: 613-619.
-
D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA 2008 Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?
Endocr. Metab. Immune Disord. Drug Targets 8: 62-68.
-
D'Cruz DP, Khamashta MA, Hughes GR 2007 Systemic lupus erythematosus.
Lancet 369: 587-596.
*
-
D’Haens G 2005 Pratical use of steroids in IBD.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 30. *
-
D'Haens G 2007 Risks and benefits of biologic therapy for inflammatory bowel diseases.
Gut 56: 725-732.
*
-
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P 2008 Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Lancet 371: 660-667.
*
-
D'Haens G, Hlavaty T 2004 Advances in medical therapy for Crohn's disease.
Curr. Gastroenterol. Rep. 6: 496-505.
-
D'Haens G, Suenaert P, Westhovens R, Rutgeerts P 1998 Severe knee pain as the single symptom of CMV infection in acute ulcerative colitis treated with cyclosporine.
Inflamm. Bowel Dis. 4: 27-28.
-
Dagfinrud H, Heiberg MS, Bakland G, Skomsvoll J, Kvien TK 2007 Ankylosing spondylitis - a consensus on diagnosis and treatment.
Tidsskr. Nor. Laegeforen. 127: 3209-3212.
-
Daikh BE, Ryan CK, Schwartz RH 2003 Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture.
Ann. Allergy Asthma Immunol. 90: 23-27.
-
Dalvi V, Gonzalez EB, Lovett L 2007 Lymphocytic interstitial pneumonitis (LIP) in Sjogren's syndrome: a case report and a review of the literature.
Clin. Rheumatol. 26: 1339-1343.
-
Danese S, Angelucci E, Malesci A, Caprilli R 2008 Biological agents for ulcerative colitis: hypes and hopes.
Med. Res. Rev. 28: 201-218.
*
-
Daneshjoo R, J Talley N 2002 Eosinophilic gastroenteritis.
Curr. Gastroenterol. Rep. 4: 366-372.
-
Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM 2008 Immune modulatory treatment of TNBS colitis with calcitriol is associated with a change of a Th1/Th17 to a Th2 and regulatory T cell profile.
J. Pharmacol. Exp. Ther. 324: 23-33.
*
-
Danowski A, Magder L, Petri M 2006 Flares in Lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone.
J. Rheumatol. 33: 57-60.
-
Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, Pera A 2004 Outcome of a conservative approach in severe ulcerative colitis.
Dig. Liver Dis. 36: 21-28.
*
-
Darlow SJ, Mandal A, Pick B, Thomas T, Mayberry JF, Robinson RJ 2004 The short-term effects of Eudragit-L-coated prednisolone metasulphobenzoate (Predocol) on bone formation and bone mineral density in acute ulcerative colitis.
Eur. J. Gastroenterol. Hepatol. 16: 1173-1176.
-
Davis GL, Czaja AJ 1981 Current concepts in the diagnosis and management of hepatitis B surface antigen-positive chronic active hepatitis.
J. Clin. Gastroenterol. 3: 381-388.
-
Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF 1982 Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis.
Mayo Clin. Proc. 57: 303-309.
-
Davis GL, Czaja AJ, Ludwig J 1984 Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis.
Gastroenterology 87: 1222-1227.
-
Davis GL, Czaja AJ, Taswell HF, Ludwig J, Go VL 1985 Hepatitis B virus replication in steroid-treated severe HBsAg-positive chronic active hepatitis.
Dig. Dis. Sci. 30: 97-103.
-
Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, Bohane TD 2006 Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach.
J. Gastroenterol. Hepatol. 21: 1609-1614.
*
-
Day CP 2005 Alcoholic liver disease.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 77. *
-
Day CP 2007 Treatment of alcoholic liver disease.
Liver Transpl. 13: S69-S75.
-
Day CP 2003 Alcoholic steatohepatitis (ASH).
Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 85-86. October 17 - 19. *
-
de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, de Boer SY, Derijks LJ, Mulder CJ 2005 Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine.
Eur. J. Gastroenterol. Hepatol. 17: 457-461.
-
de Oliveira RA, Fechine LM, Neto FC, Nicodemus JM, Silva GB Jr, Silva LS 2008 Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis.
Int. Urol. Nephrol. Jul 26 [Epub ahead of print].
-
de Saussure P, Soravia C, Morel P, Hadengue A 2005 Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis.
Aliment. Pharmacol. Ther. 22: 203-208.
*
-
De Tommaso AM, Santos DS, Novaes P, Arieta CE, Hessel G 2003 Steroid-induced cataracts in patients with autoimmune hepatitis.
Acta Gastroenterol. Latinoam. 33: 93-97.
-
De Vos M 2002 Standard and innovative therapy of inflammatory bowel diseases.
Clin. Exp. Rheumatol. 20 (6 Suppl. 28): S95-S100.
-
De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J 2003 Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450.
J. Cyst. Fibros. 2: 72-75.
-
Dear KL, Compston JE, Hunter JO 2001 Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis.
Clin. Nutr. 20: 541-546.
-
Degos F, Degott C, Erlinger S 1980 Ineffectiveness of corticosteroids in cholestatic forms of chronic active hepatitis.
Gastroenterol. Clin. Biol. 4: 246-250.
-
Deji N, Sugimoto T, Fujimoto T, Aoyama M, Takeda N, Sakaguchi M, Uzu T, Kashiwagi A 2007 Emergence of panniculitis and haemophagocytic syndrome in a patient with chronic systemic lupus erythematosus.
Lupus 16: 363-365.
-
Del Rosso Do JQ 2006 Combination topical therapy for the treatment of psoriasis.
J. Drugs Dermatol. 5: 232-234.
-
Der G, Love T, Schreck J, Horn M 2005 Primary sclerosing cholangitis: a case presentation.
Gastroenterol. Nurs. 28: 13-16.
*
-
Derijk R, de Kloet ER 2005 Corticosteroid receptor genetic polymorphisms and stress responsivity.
Endocrine 28: 263-270.
-
Desilva S, Kaplan G, Panaccione R 2008 Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.
Rev. Gastroenterol. Disord. 8: 109-116.
-
Deurloo DT, van Esch BC, Hofstra CL, Nijkamp FP, van Oosterhout AJ 2001 CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model.
Am. J. Respir. Cell. Mol. Biol. 25: 751-760.
*
-
Devlin SM, Swain MG, Urbanski SJ, Burak KW 2004 Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy.
Can. J. Gastroenterol. 18: 321-326.
-
Dhabhai R, Kalla G, Singhi MK, Ghiya BC, Kachhawa D 2005 Dexamethasone-cyclophosphamide pulse therapy in systemic lupus erythematosus.
Indian J. Dermatol. Venereol. Leprol. 71: 9-13.
*
-
Di Gangi M, Foti R, Leonardi R, Leonetti C, Castellino P 2007 Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFalpha treatment.
Reumatismo 59: 169-172.
-
Diaz-Valle D, Benitez del Castillo JM, Fernandez Acenero MJ, Pascual Allen D, Moriche Carretero M 2004 Bilateral lid margin ulcers as the initial manifestation of Crohn disease.
Am. J. Ophthalmol. 138: 292-294.
*
-
Dietrich W, Erbguth F 2003 Neurological complications of inflammatory intestinal diseases.
Fortschr. Neurol. Psychiatr. 71: 406-414.
-
Diez M, Sanchez E, Garcia Lopez S, Arroyo MT, Gomollon F 2007 Infliximab therapy in ulcerative colitis: initial experience in two referral centers.
Gastroenterol. Hepatol. 30: 449-453.
-
Diez Pina JM, Vazquez Gomez O, Mayoralas Alises S, García Jimenez JD, Alvaro Alvarez D, Rodriguez Bolado MP 2008 Etanercept as a possible trigger of fatal pulmonary fibrosis.
Arch. Bronconeumol. 44: 393-395.
*
-
Dijkstra G, Moshage H, Jansen PL 2002 Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease?
Scand. J. Gastroenterol. Suppl. 236: 37-41.
*
-
Dilger K, Alberer M, Busch A, Enninger A, Behrens R, Koletzko S, Stern M, Beckmann C, Gleiter CH 2006 Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease.
Aliment. Pharmacol. Ther. 23: 387-396.
*
-
Dilger K, Schwab M, Fromm MF 2004 Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein.
Inflamm. Bowel Dis. 10: 578-583.
*
-
Dimopoulos MA, Theodorakis M, Kostis E, Papadimitris C, Moulopoulos LA, Anastasiou-Nana M 1997 Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine.
Leuk. Lymphoma 25: 187-189.
-
Din S, Dahele A, Fennel J, Aitken S, Shand AG, Arnott ID, Satsangi J 2008 Use of methotrexate in refractory Crohn's disease: the Edinburgh experience.
Inflamm. Bowel Dis. 14: 756-762.
-
Dinarello CA 2005 Anti-cytokine therapy from the bench to the bedside.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 84-86. *
-
Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, Naccarato R, Martin A 1999 Evolution of osteopenia in inflammatory bowel disease.
Am. J. Gastroenterol. 94: 1292-1297.
*
-
Dinic-Uzurov V, Lalosevic V, Milosevic I, Urosevic I, Lalosevic D, Popovic S 2007 Current differential diagnosis of hypereosinophilic syndrome.
Med. Pregl. 60: 581-586.
-
Dinwiddie R 2005 Anti-inflammatory therapy in cystic fibrosis.
J. Cyst. Fibros. 4 Suppl. 2: S45-S48.
-
Dite P, Novotny I, Trna J, Sevcikova A 2008 Autoimmune pancreatitis.
Best Pract. Res. Clin. Gastroenterol. 22: 131-143.
-
Dittrich K, Richter M, Rascher W, Kohler H 2008 Leukocytapheresis in a girl with severe ulcerative colitis refractory to corticosteroids, infliximab, and cyclosporine A.
Inflamm. Bowel Dis. 14: 1466-1467.
-
Dolev E, Sandman-Goddard G 1989 Eosinophilic gastroenteritis.
Harefuah. 116: 465-466.
-
Donaldson PT 2005 Basic concepts in PSC.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 73-75. *
-
Donaldson PT, Czaja AJ 2002 Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis.
Clin. Liver Dis. 6: 419-437.
-
Dooley MA, Falk RJ 2007 Human clinical trials in lupus nephritis.
Semin. Nephrol. 27: 115-127.
-
Dorner T, Haas J, Loddenkemper C, von Baehr V, Salama A 2006 Implant-related inflammatory arthritis.
Nat. Clin. Pract. Rheumatol. 2: 53-56.
*
-
Doty JD, Mazur JE, Judson MA 2005 Treatment of sarcoidosis with infliximab.
Chest 127: 1064-1071.
*
-
Dray X, Joly F, Lavergne-Slove A, Treton X, Bouhnik Y, Messing B 2006 A severe but reversible refractory sprue.
Gut 55: 1210-1211.
*
-
Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ 2003 Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS)…
Rheumatology (Oxford) 42: 235-239.
*
-
Duane WC, Xiong W, Lofgren J 2008 Transactivation of the human apical sodium-dependent bile acid transporter gene by human serum.
J. Steroid Biochem. Mol. Biol. 108: 137-148.
-
Dubinsky MC 2004 Diffuse jejunoileitis in adolescence.
Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 70. May 7-8. *
-
Dubinsky MC 2006 New patients: should children be treated differently?
Colorectal Dis. 8 Suppl. 1: 15-19.
-
Dubinsky MC 2003 Optimizing immunomodulator therapy for inflammatory bowel disease.
Curr. Gastroenterol. Rep. 5: 506-511.
-
Dubinsky MC, Fleshner PP 2003 Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes.
Curr. Treat. Options Gastroenterol. 6: 183-200.
-
Duclos-Vallee JC, Di Martino V, Cazier A, Ballot E, Johanet C, Yamamoto AM, Emile JF, Guettier C, Coutarel P, Cadranel JF 2005 Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids.
Gastroenterol. Clin. Biol. 29: 1173-1176.
-
Duclos-Vallee JC, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S 1995 Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A.
Dig. Dis. Sci. 40: 1069-1073.
-
Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD 2004 Vitamin K status in patients with Crohn's disease and relationship to bone turnover.
Am. J. Gastroenterol. 99: 2178-2185.
*
-
Dunn JM, McNair A 2007 Prolonged cholestasis following successful removal of common bile duct stones: beware patients on estrogen therapy.
World J. Gastroenterol. 13: 6277-6280.
*
-
Dupont B, Dupont C, Justum AM, Piquet MA, Reimund JM 2008 Enteral nutrition in adult Crohn's disease: present status and perspectives.
Mol. Nutr. Food Res. 52: 875-884.
*
-
Durai D, Hawthorne AB 2005 Review article: how and when to use ciclosporin in ulcerative colitis.
Aliment. Pharmacol. Ther. 22: 907-916.
*
-
Durox H, Boumediene A, Genet C, Lo Re P, Rogez JP, Weinbreck P, Denes E 2007 Disseminated aspergillosis after intra-articular corticosteroid infiltrations.
Med. Mal. Infect. 37: 609-612.
-
Dwarakanath AD, Nash J, Rhodes JM 1994 'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment.
Gut 35: 1141-1144.
*
-
Dziechciarz P, Horvath A, Shamir R, Szajewska H 2007 Meta-analysis: enteral nutrition in active Crohn's disease in children.
Alime
| |
